Events

At this networking meeting, patent experts from Høiberg A/S will talk about why it is still possible to patent personalized medicine and diagnostic methods following the recent decision (Mayo vs. Prometheus) from the US Supreme Court? You will be guide through the aftermath of the Prometheus decision. Additionally the meeting will focus on strategies to […]

Members of Medicon Valley Alliance are invited to attend the Ordinary General Meeting 2012. Agenda Election of chairperson. The Board of Directors’ report on MVA’s activities in the past year. Presentation of the annual report, including auditor’s report, adoption of the annual report and the establishment of the Board of Director’s remuneration. Resolution on the […]

17 April 2012 / Ørestad / Denmark Medicon Valley Alliance in cooperation with DNB invites you to participate in a network meeting on how to attract investors and industry partners to a life science company. At the meeting you will also have the opportunity to present you technology / business plan to any of the […]

Hear about MVA and our networks and initiatives. Get an insight into what value your organization gains from your membership of MVA.  Learn more about how MVA works to maintain and develop the attractiveness of Medicon Valley. 22 March 2012 / Ørestad / Denmark Join other members and non-members at the introductory meeting to MVA […]

This seminar will address several of todays key challenges in drug development leading up to clinical proof of concept. The agenda brings together a panel of speakers from academia, pharmaceutical companies and solution providers to discuss key issues from formulation design right through to effective clinical trial planning. The final session w ill discuss how […]

Organotypic 3D-cell-culture systems are implemented at various stages in the compound development process for de-risking new drug candidates and can provide a wealth of meaningful efficacy and toxicology data. A growing list of publications confirms the striking similarities of these systems to in vivo tissue, clearly underlining their high potential value to the pharmaceutical industry. […]